ERIC J SORSCHER, MD
Osteopathic Medicine at 19 St, Birmingham, AL

6605281, Aug 12, 2003

Jul 17, 2000

09/530047

Thomas R. Broker - Mountain Brook AL
Louise T. Chow - Mountain Brook AL
Eric J. Sorscher - Birmingham AL
Nianxiang Zou - Homewood AL
Vijayakrishna K. Gadi - Birmingham AL

The UAB Research Foundation - Birmingham AL

A61K 3912

4241991, 4242041, 4353201, 435 691, 4352351, 435325, 4352523, 536 2372, 536 231

A replicon for delivery of a transgene for episomal gene expression in a mammalian host cell includes a transgene having an open reading frame or other nucleic acid sequence for transcription into RNA and under the transcriptional control of a first surrogate promoter and a first gene sequence expressing a papillomavirus replication initiator protein E1 tinder tile control of a second surrogate promoter. The replicon also includes second gene sequence expressing the papillomavirus replication origin binding protein E2 under the control of a third surrogate promoter, wherein tile transgene, the first and the second sequences are incorporated within at least one plasmid and less than three plasmids.

2004020, Oct 14, 2004

Nov 3, 2003

10/476754

Eric Sorscher - Birmingham AL, US
Jeong Hong - Birmingham AL, US
Jennifer Harris - Birmingham AL, US
Kimberly Curlee - Phoenix AZ, US
Joseph Maddry - Birmingham AL, US
William Parker - Birmingham AL, US
William Wand - Mountain Brook AL, US

A61K048/00, A61K031/7076, A61K031/15

514/044000, 514/046000, 514/639000

Compounds having the structure: wherein R, Rand Rare each independently a Csubstituent selected from the group consisting of: hydrogen, a heteroatom, alkyl, alkenyl, alkynyl, heteroatom substituted alkyl, heteroatom substituted alkenyl, heteroatom substituted alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl; where the heteroatom is selected from the group consisting of: N, O and S; and where (A) is a single or double bond between N and R. Further the Csubstituent is linear, branched or cyclic and optionally includes a pendant moiety selected from the group consisting of: carbonyl, hydroxyl, carboxyl, amine, thiol, thioester, thioether, phosphate, alkoxy, aryl, arylalkyl, sulfonamide and alkyl halide. Further, compounds 6883, 6898, 6975, 7036, 7064 and 8496 are provided. A process is provided for activating gene transfer in a subject by administering a pharmaceutically effective amount of a gene transfer activating compound to a subject and delivering pharmaceutically effective amount of a vector containing a nucleic so that the nucleic acid is transcribed in a target cell of the subject. A process for activating gene transfer to a cell is provided. A kit for activating gene transfer is provided.

7037718, May 2, 2006

Oct 26, 2001

10/035300

Steven E. Ealick - Ithaca NY, US
William B. Parker - Birmingham AL, US
Eric J. Sorscher - Birmingham AL, US

Cornell Research Foundation, Inc. - Ithaca NY
Southern Research Institute - Birmingham AL
The UAB Research Foundation - Birmingham AL

C12N 15/85

435325, 4352523, 536 231, 514 44

The present invention provides a procaryotic host cell stably transformed or transfected by a vector including a DNA sequence encoding for mutant purine nucleoside phosphorylase or hydrolase. The transformed or transfected procaryotic host cell can be used in combination with a purine substrate to treat tumor cells and/or virally infected cells. The present invention provides nucleotide sequences encoding mutant derived purine nucleoside phosphorylase proteins which can be used in conjunction with an appropriate substrate to produce toxins which impair abnormal cell growth. The invention provides for delivery of the toxin by generation within target cells or by administration and delivery to the cells from without.

2010015, Jun 17, 2010

May 16, 2006

11/914563

Eric J. Sorscher - Birmingham AL, US
William B. Parker - Birmingham AL, US
Jeong S. Hong - Birmingham AL, US

C12N 5/02, C12N 15/63

435375, 4353201

Described are methods and compositions for inhibiting undesired cells by expression of one or more exogenous enzymes in the cells and administration of a prodrug which is a substrate for at least one of the enzymes to produce a cytotoxic compound. Inventive methods and compositions are active to inhibit cells expressing the exogenous enzymes as well as bystander cells. Tumor cells are a particular target for inhibition using methods and compositions detailed according to the present invention. Provided are methods and compositions for improved anti-tumoral effects by overexpression of adenine phosphoribosyltransferase (APRT) to produce cytotoxins which inhibit the cells overexpressing the APRT as well as bystander cells. Overexpression of APRT in conjunction with expression of PNP and administration of a substrate for PNP provides particularly effective anti-tumoral effects.

6958318, Oct 25, 2005

Jul 18, 2002

10/198034

Eric J. Sorscher - Birmingham AL, US
William B. Parker - Birmingham AL, US
William Waud - Mountain Brook AL, US
Vijayakrishna K. Gadi - Birmingham AL, US

The UAB Research Foundation - Birmingham AL
Southern Research Institute - Birmingham AL

A01N037/18, C07K001/00, C07K014/00

514 2, 530350

The present invention provides a procaryotic host cell stably transformed or transfected by a vector including a DNA sequence encoding for purine nucleoside phosphorylase or hydrolase. The transformed or transfected procaryotic host cell can be used in combination with a purine substrate to treat tumor cells and/or virally infected cells.

2003013, Jul 17, 2003

Jul 18, 2002

10/198228

Eric Sorscher - Birmingham AL, US
William Parker - Birmingham AL, US
William Waud - Mountain Brook AL, US
Vijayakrishna Gadi - Birmingham AL, US
Leonard Bennett - Birmingham AL, US

A61K031/7076, A61K031/522, A61K031/519

514/046000, 514/263300, 514/263370, 514/265100

The present invention provides a procaryotic host cell stably transformed or transfected by a vector including a DNA sequence encoding for purine nucleoside phosphorylase or hydrolase. The transformed or transfected procaryotic host cell can be used in combination with a purine substrate to treat tumor cells and/or virally infected cells.

2002003, Mar 21, 2002

Apr 30, 2001

09/843796

Joseph Maddry - Birmingham AL, US
Eric Sorscher - Birmingham AL, US

Southern Research Institute - Birmingham AL

A61K031/4166, A61K031/4152, A61K031/4196

514/398000, 514/384000, 514/404000

Compounds represented by formula (I), wherein A is a 5 or 6-membered unsaturated heterocyclic ring containing at least one N atom; B is Xis O, NH, NR, CH, CHR or CR, each R individually is alkyl, cycloalkyl, aryl, alkaryl and aralkyl, each Rindividually is H, alkyl, cycloalkyl, aryl, alkaryl, and aralkyl; Y is a halogen; alkythio group or nitrogenous moiety, are useful for activating Cl secretion, and can be used for treating cystic fibrosis.

7473527, Jan 6, 2009

Jul 2, 2003

10/520377

Eric J. Sorscher - Birmingham AL, US

The UAB Research Foundation - Birmingham AL

C12Q 1/68

435 6, 435455, 424450

A process is provided for activating gene transfer in a cell by administering a gene transfer activating compound to the cell in conjunction with a gene transfer vector. A kit for activating gene transfer as well as process for identifying a compound that activates gene transfer are described. Use of a gene transfer activator compound enhances gene transfer of a given gene transfer vector.